These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. Yusuf MB; Amsbaugh MJ; Burton E; Chesney J; Woo S World Neurosurg; 2017 Apr; 100():632-640.e4. PubMed ID: 28179176 [TBL] [Abstract][Full Text] [Related]
23. Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016. Brastianos HC; Nguyen P; Sahgal A; Eisenhauer EA; Baetz T; Hanna TP JAMA Netw Open; 2020 Jul; 3(7):e208204. PubMed ID: 32663310 [TBL] [Abstract][Full Text] [Related]
24. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Iorgulescu JB; Harary M; Zogg CK; Ligon KL; Reardon DA; Hodi FS; Aizer AA; Smith TR Cancer Immunol Res; 2018 Sep; 6(9):1039-1045. PubMed ID: 30002157 [TBL] [Abstract][Full Text] [Related]
25. Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China. Wang Y; Lian B; Si L; Chi Z; Sheng X; Wang X; Mao L; Tang B; Li S; Yan X; Bai X; Zhou L; Cui C; Guo J J Cancer Res Clin Oncol; 2021 Sep; 147(9):2731-2740. PubMed ID: 33611636 [TBL] [Abstract][Full Text] [Related]
26. Real-world data on melanoma brain metastases and survival outcome. Pedersen S; Møller S; Donia M; Persson GF; Svane IM; Ellebaek E Melanoma Res; 2022 Jun; 32(3):173-182. PubMed ID: 35256571 [TBL] [Abstract][Full Text] [Related]
27. Survival and prognostic factors in patients with brain metastases from malignant melanoma. Meier S; Baumert BG; Maier T; Wellis G; Burg G; Seifert B; Dummer R Onkologie; 2004 Apr; 27(2):145-9. PubMed ID: 15138346 [TBL] [Abstract][Full Text] [Related]
28. The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis. Rulli E; Legramandi L; Salvati L; Mandala M Cancer; 2019 Nov; 125(21):3776-3789. PubMed ID: 31287564 [TBL] [Abstract][Full Text] [Related]
29. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. Kaidar-Person O; Zagar TM; Deal A; Moschos SJ; Ewend MG; Sasaki-Adams D; Lee CB; Collichio FA; Fried D; Marks LB; Chera BS Anticancer Drugs; 2017 Jul; 28(6):669-675. PubMed ID: 28368903 [TBL] [Abstract][Full Text] [Related]
30. Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era? Badakhshi H; Engeling F; Budach V; Ghadjar P; Zschaeck S; Kaul D Radiat Oncol; 2018 Jan; 13(1):3. PubMed ID: 29316943 [TBL] [Abstract][Full Text] [Related]
31. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Chowdhury IH; Ojerholm E; McMillan MT; Miller D; Kolker JD; Kurtz G; Dorsey JF; Nagda SN; Geiger GA; Brem S; O'Rourke DM; Zager EL; Gangadhar T; Schuchter L; Lee JY; Alonso-Basanta M Radiat Oncol; 2015 Dec; 10():248. PubMed ID: 26626714 [TBL] [Abstract][Full Text] [Related]
32. Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence. de Castro DG; Teixeira CHA; Gondim GRM; Aguilar PB; Costa MASB; Jorge TWC; Morais Hanriot R Clin Transl Oncol; 2022 Sep; 24(9):1828-1830. PubMed ID: 35546648 [TBL] [Abstract][Full Text] [Related]
33. Radiotherapy in combination with systemic therapies for brain metastases: current status and progress. Liu L; Chen W; Zhang R; Wang Y; Liu P; Lian X; Zhang F; Wang Y; Ma W Cancer Biol Med; 2020 Nov; 17(4):910-922. PubMed ID: 33299643 [TBL] [Abstract][Full Text] [Related]
34. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Hara W; Tran P; Li G; Su Z; Puataweepong P; Adler JR; Soltys SG; Chang SD; Gibbs IC Neurosurgery; 2009 Feb; 64(2 Suppl):A26-32. PubMed ID: 19165071 [TBL] [Abstract][Full Text] [Related]
35. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540 [TBL] [Abstract][Full Text] [Related]
36. Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy. Salzmann M; Hess K; Lang K; Enk AH; Jordan B; Hassel JC Strahlenther Onkol; 2022 Oct; 198(10):884-891. PubMed ID: 35546362 [TBL] [Abstract][Full Text] [Related]
37. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. Tétu P; Allayous C; Oriano B; Dalle S; Mortier L; Leccia MT; Guillot B; Dalac S; Dutriaux C; Lacour JP; Saiag P; Brunet-Possenti F; De Quatrebarbes J; Stoebner PE; Legoupil D; Beylot-Barry M; Lesimple T; Aubin F; Dreno B; Mohamed S; Ballon A; Porcher R; Lebbe C Eur J Cancer; 2019 May; 112():38-46. PubMed ID: 30909072 [TBL] [Abstract][Full Text] [Related]
38. Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. Huttenlocher S; Sehmisch L; Schild SE; Blank O; Hornung D; Rades D Anticancer Res; 2014 Oct; 34(10):5589-92. PubMed ID: 25275060 [TBL] [Abstract][Full Text] [Related]
39. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Franceschini D; Franzese C; Navarria P; Ascolese AM; De Rose F; Del Vecchio M; Santoro A; Scorsetti M Cancer Treat Rev; 2016 Nov; 50():1-8. PubMed ID: 27566962 [TBL] [Abstract][Full Text] [Related]